Testosterone Cypionate Blood Work Guide: What to Test, When to Test, and How to Read Your Results

Blood work is the single most important tool for managing a testosterone cypionate protocol safely and effectively. Without it, you are guessing. With it, every decision, from dose adjustments to ancillary use to whether to extend a cycle, is grounded in objective data rather than subjective feel. This guide from Hemi Pharma UK covers every blood test relevant to testosterone cypionate use, when to draw each one, how to interpret the results, and what actions each result should trigger. Whether you are on TRT or a performance cycle, this is the reference you should bookmark.

Key Takeaways

  • The minimum blood work schedule for testosterone cypionate is three draws: baseline (pre-cycle), mid-cycle (week 6), and post-PCT (4+ weeks after completing PCT). TRT users should test at 6 to 8 weeks, 3 months, and then annually.
  • Always draw blood at trough: the morning before your next injection, when testosterone is at its lowest point. Peak-drawn blood artificially inflates your numbers and leads to unnecessary dose reductions.
  • The five critical markers on every draw are total testosterone, oestradiol (sensitive assay), haematocrit, HDL cholesterol, and PSA (men over 40). These are the markers that drive the most common and most important clinical decisions.
  • The Endocrine Society and BSSM guidelines both recommend haematocrit monitoring at baseline, 3 to 6 months, and annually, with a threshold of 54% for dose reduction or intervention.
  • A 2023 UK audit found that 35% of patients on testosterone therapy did not have their haematocrit rechecked at 3 to 6 months, despite this being a core safety marker. Self-managed blood work through private services fills this gap for users who are not under direct medical supervision.

What Blood Tests Do You Need on Testosterone Cypionate?

The Endocrine Society Clinical Practice Guideline on testosterone therapy (Bhasin et al., 2018) and the BSSM 2023 guidelines both provide detailed monitoring recommendations. The following table consolidates the clinical guidelines with practical additions for performance users who require broader monitoring than standard TRT protocols.

Marker What It Measures Why It Matters for Testosterone Cypionate Target Range Action If Out of Range
Total Testosterone Total circulating testosterone (bound + free) Confirms your dose is producing the intended serum level at trough TRT: 15 to 30 nmol/L at trough. Cycle: dose-dependent Below target: increase dose by 25 to 50mg. Above: reduce dose
Free Testosterone Unbound, bioactive testosterone More clinically relevant than total T; not affected by SHBG variations Lab-specific; generally 0.225 to 0.725 nmol/L Low despite adequate total T: SHBG may be high; consider SHBG-lowering strategies
SHBG Sex hormone-binding globulin High SHBG binds more T, reducing free T; explains discrepancy between total and free T 10 to 70 nmol/L Very high: free T will be lower than total T suggests. Very low: free T and E2 may be disproportionately high
Oestradiol (Sensitive/LC-MS) Primary oestrogen; produced via aromatisation of testosterone Guides AI use; elevated E2 causes water retention, gynecomastia, mood issues Sensitive assay: 70 to 200 pmol/L (varies by lab) Elevated with symptoms: increase injection frequency first; add anastrozole 0.25mg if persistent. Crashed: discontinue AI immediately
Haematocrit Percentage of blood volume occupied by red blood cells Testosterone stimulates erythropoietin; elevated HCT increases viscosity and CV risk Below 52% preferred; 54% is the clinical intervention threshold Above 52%: increase frequency, hydrate. Above 54%: reduce dose, consider phlebotomy. Full CV guide
Haemoglobin Oxygen-carrying protein in red blood cells Rises alongside haematocrit; >18 g/dL warrants attention 13.0 to 17.5 g/dL Follows haematocrit management protocol
Full Blood Count (FBC) Comprehensive red and white cell panel Broader picture than haematocrit alone; detects anomalies Lab reference ranges Refer if white cells or platelets are abnormal (unlikely to be testosterone-related)
Lipid Panel Total cholesterol, HDL, LDL, triglycerides Supraphysiological T suppresses HDL; cardiovascular risk marker HDL above 1.0 mmol/L; LDL below 3.0 mmol/L; triglycerides below 2.3 mmol/L HDL below 0.8: consider whether dose/compound is necessary. Include omega-3 and cardio
Liver Function (ALT, AST, GGT) Liver enzyme markers Injectable testosterone is not hepatotoxic; baseline needed for comparison if adding oral compounds Lab reference ranges Significant elevation on injectable T only: investigate other causes (alcohol, supplements, other drugs)
Kidney Function (Creatinine, eGFR) Renal filtration and function Kidney health monitoring; elevated creatinine may reflect increased muscle mass, not renal damage eGFR above 60; creatinine within lab range (note: muscular men often have higher creatinine) eGFR declining over time: warrants investigation. Single elevated creatinine in a muscular man: likely benign
PSA Prostate-specific antigen Prostate monitoring; recommended for all men over 40 on testosterone Below 4.0 ng/mL; velocity below 0.4 ng/mL per year Rise above 1.4 ng/mL in 12 months or above 4.0 total: urological referral
LH and FSH Luteinising hormone and follicle-stimulating hormone Suppressed to near-zero during exogenous testosterone; useful for confirming recovery post-PCT On cycle: will be near zero. Post-PCT: should return to pre-cycle range Still suppressed 8+ weeks post-PCT: recovery may be incomplete; consider extended SERM or referral
Prolactin Pituitary hormone Not affected by testosterone cypionate alone; only relevant when stacking with 19-nor compounds 86 to 324 mIU/L Elevated on testosterone-only: investigate other causes (stress, medication, pituitary)

When Should You Draw Blood on Testosterone Cypionate?

Timing is as important as the test itself. Drawing blood at the wrong point in your dosing cycle produces misleading results that lead to incorrect dose adjustments.

Protocol Stage When to Draw Purpose Key Markers
Baseline (pre-cycle or pre-TRT) Before first injection; morning (8 to 10am) Establishes your natural levels and health markers for comparison All markers in the table above
Mid-cycle (first cycle) Week 6; morning; at trough (before next injection) Confirms steady-state testosterone, checks oestradiol, haematocrit Total T, free T, E2, haematocrit, FBC, lipids
Late cycle (extended or second+ cycle) Week 12; morning; at trough Confirms markers remain stable before deciding whether to extend All markers; especially haematocrit, lipids, LFTs
Post-PCT recovery 4+ weeks after completing PCT; morning (8 to 10am) Confirms HPT axis recovery; LH, FSH, and T should return to baseline Total T, free T, LH, FSH, E2
TRT ongoing 6 to 8 weeks after starting; 3 months; then annually BSSM recommended monitoring schedule Total T, haematocrit, PSA (men over 40), lipids annually

Why Trough Timing Matters

Drawing blood at trough (the morning before your next injection) ensures you measure your lowest level in the dosing cycle. This is clinically the most useful number because it tells you whether your minimum level is adequate. If your trough is within the target range, then your levels throughout the rest of the week are necessarily higher and likely more than sufficient.

A blood test drawn 24 to 48 hours after injection captures your near-peak level, which can be 50 to 100% higher than trough depending on dose and frequency. Using a peak value to adjust your dose downward (because it “looks too high”) means your trough drops below the therapeutic range, potentially leaving you symptomatic for the second half of each dosing interval. The half-life guide explains the concentration curve that makes trough timing so important.

How Do You Interpret Your Testosterone Cypionate Blood Work?

Raw numbers mean nothing without context. The following interpretation framework covers the most common results patterns and what they indicate for your protocol.

Result Pattern What It Means Action
Trough T below target; no symptoms Dose may be insufficient, or clearance faster than average Increase by 25mg/week; retest at 6 weeks
Trough T below target; symptoms (fatigue, low libido) Dose definitely insufficient Increase by 25 to 50mg/week; retest at 6 weeks
Trough T in target; feel good; markers normal Protocol is correct Hold dose; retest at next scheduled interval
Trough T above target (TRT); no side effects Dose higher than needed for therapeutic replacement Consider reducing by 25mg/week; higher levels increase cumulative side effect exposure
E2 elevated; no symptoms Aromatisation is occurring but not causing clinical issues Monitor only; oestradiol has beneficial effects at moderate levels
E2 elevated; symptoms (water retention, nipple sensitivity, mood) Aromatisation is producing clinically relevant oestradiol excess Increase injection frequency first. If persistent: anastrozole 0.25mg on injection days
E2 crashed (below 70 pmol/L on sensitive assay) AI dose is too high, or aromatisation is very low Stop AI immediately; E2 is essential for joints, bones, mood, and cardiovascular health
Haematocrit 50 to 52% Trending up but not yet at intervention threshold Increase injection frequency; ensure adequate hydration; monitor trend
Haematocrit 52 to 54% Approaching clinical threshold Increase frequency; reduce dose if needed; consider phlebotomy referral
Haematocrit above 54% Clinical risk: blood viscosity is significantly elevated Reduce dose; arrange therapeutic phlebotomy; consider whether current protocol is sustainable
HDL below 1.0 mmol/L Androgen-mediated suppression of HDL Ensure adequate omega-3 intake; include regular cardio; this is dose-dependent and reversible
PSA rise above 1.4 ng/mL in 12 months May indicate prostatic response to androgens Urological referral per prostate health guidelines
LH/FSH still suppressed 8+ weeks post-PCT HPT axis recovery is incomplete Extended SERM course or specialist referral; the cycle length guide covers recovery expectations

Where Can UK Users Get Private Blood Work for Testosterone Cypionate?

Many testosterone cypionate users in the UK are not under direct medical supervision and cannot easily access the full blood panel through their GP, either because they have not disclosed their use or because their GP does not offer the comprehensive panel needed. Private blood testing services bridge this gap.

Multiple UK-based services offer “male hormone” or “TRT monitoring” blood panels that include the key markers: total testosterone, free testosterone, SHBG, oestradiol, haematocrit/FBC, lipids, liver function, kidney function, and PSA. These are typically offered as either a venous blood draw at a clinic or a finger-prick home test kit. Venous draws are more accurate for haematocrit and hormone levels; finger-prick kits are adequate for tracking trends over time but may have slightly higher variability on individual readings.

The cost typically ranges from £50 to £150 per panel depending on the breadth of markers. This is a modest investment relative to the cost of the testosterone itself and the potential health consequences of running unmonitored. If you can afford to buy testosterone cypionate, you can afford to monitor it.

If you do choose to discuss your testosterone cypionate use with your GP, the guide on talking to your GP covers how to frame the conversation and request the specific blood tests that matter. Many GPs are willing to run monitoring blood work even for patients who are self-managing, because monitoring reduces the health risks that concern them most.

What Mistakes Do Users Make with Testosterone Cypionate Blood Work?

First, not getting it at all. A 2023 UK audit presented at the Society for Endocrinology found that 35% of patients on prescribed TRT did not have their haematocrit rechecked at 3 to 6 months, despite haematocrit being one of the most important safety markers. If compliance is this poor within the medical system, it is likely worse among self-managed users. Skipping blood work is the highest-risk behaviour in testosterone cypionate use, period.

Second, drawing at peak instead of trough. A testosterone level drawn 24 hours after injection will show a much higher number than the same person’s level drawn 7 days after injection (at trough). Using the peak number to judge your dose leads to unnecessary reductions. The half-life guide explains why trough timing is the clinical standard.

Third, using standard immunoassay for oestradiol instead of the sensitive (LC-MS/MS) assay. The standard immunoassay was designed for female reproductive hormone levels and is inaccurate at the lower concentrations found in males. It can over-report oestradiol by up to 50%, leading to unnecessary AI use that crashes E2 and produces worse symptoms than the elevated oestradiol would have caused. Always request the sensitive or LC-MS/MS oestradiol assay.

Fourth, changing dose immediately after one set of results. It takes approximately 4 to 5 half-lives (32 to 40 days for testosterone cypionate) to reach a new steady state after a dose change. Adjusting dose and retesting within 2 to 3 weeks means you are measuring levels before the previous change has fully taken effect, creating a cycle of unnecessary adjustments. Wait a minimum of 6 weeks between dose changes before retesting.

Fifth, ignoring markers because they are “only slightly out of range.” A haematocrit of 53% is within some lab reference ranges but is trending toward the 54% intervention threshold. Blood pressure at 138/88 is technically below the 140/90 hypertension threshold but is elevated and heading in the wrong direction. Tracking trends over multiple blood draws is more informative than treating any single result in isolation.

How Does Using Verified Product Affect Your Blood Work Accuracy?

The accuracy of your blood work interpretation depends on knowing your actual dose. If you are injecting what you believe is 200mg/mL testosterone cypionate but the product actually contains 150mg/mL, your blood work will show lower testosterone levels than expected. You might then increase your dose based on those results, overshooting your intended target once you switch to an accurately dosed product. Alternatively, your blood work might show acceptable testosterone but unexpectedly low oestradiol and stable haematocrit, because the effective dose is lower than intended.

Every batch of Hemi Pharma testosterone cypionate is tested by Janoshik Analytical, confirming concentration accuracy. When you know your product contains exactly 200mg/mL, your dosing calculations are correct, your blood work results correspond to your intended dose, and your protocol adjustments are based on accurate data. This is the foundation that makes blood-work-guided dosing meaningful rather than an exercise in guessing the concentration of an unknown product.

Frequently Asked Questions

What blood tests do I need before starting testosterone cypionate?

A complete baseline panel should include total testosterone, free testosterone, SHBG, oestradiol (sensitive assay), LH, FSH, full blood count (including haematocrit), liver function, kidney function, lipid panel, and PSA (men over 40). These values become your personal reference points for every future blood draw. Without a baseline, you cannot assess whether changes during your cycle represent a genuine shift or simply reflect your natural levels.

When should I get blood work during a testosterone cypionate cycle?

At minimum: baseline (before first injection), mid-cycle (week 6), and post-PCT (4+ weeks after completing PCT). For cycles extending beyond 12 weeks, add a draw at week 12 before deciding to continue. Always draw at trough (the morning before your next injection) for consistent, comparable results.

Can I get testosterone cypionate blood work through my GP?

Yes, if you disclose your use. GMC confidentiality guidelines protect this conversation, and most GPs will run monitoring blood work even for self-managed use because it reduces health risks. The GP communication guide covers how to approach this conversation. If you prefer not to disclose, private blood testing services in the UK offer comprehensive panels for £50 to £150 per draw.

What is the most important blood test on testosterone cypionate?

Haematocrit. While testosterone and oestradiol levels guide dose and ancillary decisions, haematocrit is the safety-critical marker that identifies the risk of a potentially life-threatening event (stroke, DVT, pulmonary embolism). The Endocrine Society and BSSM both mandate haematocrit monitoring at every blood draw, with a 54% threshold for dose reduction or phlebotomy. If you test only one thing, test haematocrit.

How much does private blood work cost in the UK?

A comprehensive TRT or steroid monitoring panel typically costs £50 to £150 depending on the provider and the number of markers included. Venous blood draws at a clinic are at the higher end and provide the most accurate results. Finger-prick home kits are cheaper and convenient but have slightly more variability. The cost is modest relative to the health protection it provides, and most experienced users consider it a non-negotiable part of their protocol budget.

References

Bhasin, S., Brito, J.P., Cunningham, G.R., Hayes, F.J., Hodis, H.N., Matsumoto, A.M., Snyder, P.J., Swerdloff, R.S., Wu, F.C. and Yialamas, M.A. (2018) ‘Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline’, Journal of Clinical Endocrinology and Metabolism, 103(5), pp. 1715-1744. Available at: https://pubmed.ncbi.nlm.nih.gov/29562364/ (Accessed: 5 November 2026).

Hackett, G., Kirby, M., Edwards, D., Jones, T.H., Wylie, K., Ossei-Gerning, N., David, J. and Muneer, A. (2023) ‘The British Society for Sexual Medicine Guidelines on Male Adult Testosterone Deficiency, with Statements for Practice’, World Journal of Men’s Health, 41(3), pp. 508-537. Available at: https://pubmed.ncbi.nlm.nih.gov/36876744/ (Accessed: 5 November 2026).

Calof, O.M., Singh, A.B., Lee, M.L., Kenny, A.M., Urban, R.J., Tenover, J.L. and Bhasin, S. (2005) ‘Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials’, Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 60(11), pp. 1451-1457. Available at: https://pubmed.ncbi.nlm.nih.gov/16339542/ (Accessed: 5 November 2026).

Rhoden, E.L. and Morgentaler, A. (2004) ‘Risks of testosterone-replacement therapy and recommendations for monitoring’, New England Journal of Medicine, 350(5), pp. 482-492. Available at: https://pubmed.ncbi.nlm.nih.gov/14749459/ (Accessed: 5 November 2026).

El-Khatib, F.M., Osman, M.M., Huynh, L.M., Dianatnejad, S., Wu, Q. and Yafi, F.A. (2022) ‘Comparative assessment of outcomes and adverse effects using two different intramuscular testosterone therapy regimens: 100 mg IM weekly or 200 mg IM biweekly’, International Journal of Impotence Research, 34(6), pp. 558-563. Available at: https://pubmed.ncbi.nlm.nih.gov/34257404/ (Accessed: 5 November 2026).

Shopping Basket
Scroll to Top